Literature DB >> 28362548

Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.

Giannis Sokratous1, Stavros Polyzoidis2,3, Keyoumars Ashkan4.   

Abstract

Autologous dentritic cell immunotherapy has been proven effective in treating tumors outside the central nervous system. Current evidence from phase I and II trials suggest a similar efficacy for central nervous system tumors as well and that an active immune response against these tumors can be generated. We aim to review the literature to identify the types of immune responses against gliomas found to be generated by dendritic cell vaccinations and the types of immune cells subsequently infiltrating the glioma microenvironment. A systematic review of the literature was performed by searching the online databases PubMEd, Google Scholar, and EMBASE with use of the keywords intratumoral, infiltration, lymphocytic, vaccination and gliomas. Seven studies reporting lymphocytic infiltration of gliomas microenvironment were identified. Three studies (42.8%) reported presence of tumor infiltrating lymphocytes in 50%, 50% and 28.6% of included patients respectively in the post-vaccination specimens that were not present in the pre-vaccination samples. The remaining 4 (57.2%) reported an up to 6-fold increase in the number of pre-existing lymphocytes following vaccination. Present data indicate that tumor infiltration by lymphocytes can be induced by dentritic cell immunotherapy and that this may positively affect clinical outcome. It still remains unclear which factors influence the above reaction and therefore prediction of response to treatment is still not possible.

Entities:  

Keywords:  Intratumoral; glioma; infiltration; lymphocytic; vaccination

Mesh:

Year:  2017        PMID: 28362548      PMCID: PMC5703406          DOI: 10.1080/21645515.2017.1303582

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  49 in total

Review 1.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 2.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

3.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

Authors:  L M Liau; K L Black; R M Prins; S N Sykes; P L DiPatre; T F Cloughesy; D P Becker; J M Bronstein
Journal:  J Neurosurg       Date:  1999-06       Impact factor: 5.115

4.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

5.  Dendritic cells loading autologous tumor lysate promote tumor angiogenesis.

Authors:  Yi Yang; Jing Lu; Hangfan Liu; Guoguo Jin; Ruihua Bai; Xiang Li; Dongyu Wang; Jimin Zhao; Youtian Huang; Kangdong Liu; Ying Xing; Ziming Dong
Journal:  Tumour Biol       Date:  2016-10-10

6.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

7.  Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.

Authors:  Katharina Ochs; Felix Sahm; Christiane A Opitz; Tobias V Lanz; Iris Oezen; Pierre-Olivier Couraud; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

8.  Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

Authors:  Hans Herbert Steiner; Matteo Mario Bonsanto; Philipp Beckhove; Michael Brysch; Karsten Geletneky; Rezvan Ahmadi; Rebecca Schuele-Freyer; Paul Kremer; Golamreza Ranaie; Dejana Matejic; Harald Bauer; Marika Kiessling; Stefan Kunze; Volker Schirrmacher; Christel Herold-Mende
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

9.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.

Authors:  L Palma; N Di Lorenzo; B Guidetti
Journal:  J Neurosurg       Date:  1978-12       Impact factor: 5.115

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  44 in total

1.  Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.

Authors:  Paula Alcaide-Leon; Tracy L Luks; Marisa Lafontaine; Janine M Lupo; Hideho Okada; Jennifer L Clarke; Javier E Villanueva-Meyer
Journal:  J Neurooncol       Date:  2019-11-14       Impact factor: 4.130

2.  Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.

Authors:  Xian-Ning Wu; Dan Su; Yi-De Mei; Mei-Qing Xu; Hao Zhang; Ze-Yu Wang; Li-Ling Li; Li Peng; Jun-Yi Jiang; Jia-Yi Yang; Dong-Jie Li; Hui Cao; Zhi-Wei Xia; Wen-Jing Zeng; Quan Cheng; Nan Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-03-03       Impact factor: 6.968

3.  Tripartite motif-containing 25 facilitates immunosuppression and inhibits apoptosis of glioma via activating NF-κB.

Authors:  Mao-Xu Ge; Yi-Kang Shi; Dong Liu
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-20

Review 4.  Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.

Authors:  Qianquan Ma; Wenyong Long; Changsheng Xing; Junjun Chu; Mei Luo; Helen Y Wang; Qing Liu; Rong-Fu Wang
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

5.  Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.

Authors:  Zhi-Liang Wang; Zheng Wang; Guan-Zhang Li; Qiang-Wei Wang; Zhao-Shi Bao; Chuan-Bao Zhang; Tao Jiang
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

6.  Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.

Authors:  Jenny Bulgarelli; Marcella Tazzari; Anna Maria Granato; Laura Ridolfi; Serena Maiocchi; Francesco de Rosa; Massimiliano Petrini; Elena Pancisi; Giorgia Gentili; Barbara Vergani; Filippo Piccinini; Antonella Carbonaro; Biagio Eugenio Leone; Giovanni Foschi; Valentina Ancarani; Massimo Framarini; Massimo Guidoboni
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

7.  Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.

Authors:  Weijie Qiang; Yifei Dai; Guibo Sun; Xiaoyan Xing; Xiaobo Sun
Journal:  Ann Transl Med       Date:  2020-03

8.  CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.

Authors:  Peng Xu; XiaoLan Xu; Xiao Wu; LiXiang Zhang; Lei Meng; ZhangMing Chen; WenXiu Han; Jie Yao; AMan Xu
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

Review 9.  Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.

Authors:  Juri Kiyokawa; Hiroaki Wakimoto
Journal:  Oncolytic Virother       Date:  2019-10-24

10.  LC3B in Malignant Cells Correlates With Immune Infiltrate in Hypopharyngeal Squamous Cell Carcinoma.

Authors:  Sifan Gao; Jun Chen; Xiaowen Han; Dangjun Wei; Zhengsheng Wu; Chaobing Gao
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.